We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Tocilizumab Exerts Anti-Tumor Effects on Colorectal Carcinoma Cell Xenografts Corresponding to Expression Levels of Interleukin-6 Receptor.
- Authors
Chung, Yuan-Chiang; Chen, Szu-Jung; Huang, Chiu-Chen; Liu, Wei-Chun; Lai, Ming-Tsung; Kao, Ting-Yu; Yang, Wei-Shun; Yang, Chien-Hui; Hsu, Chih-Ping; Chang, Jia-Feng
- Abstract
The use of tocilizumab against the interleukin-6 receptor (IL-6R) has been demonstrated as inhibiting the progression of diverse cancers in vitro and in vivo. Nonetheless, evidence regarding the anti-tumor effects of tocilizumab on human colorectal carcinoma (CRC) corresponding to IL-6R expression levels remains scarce. To investigate the influence of IL-6R expression, SW480 and HT-29 cells inoculated subcutaneously into NU/NU mice were used as human CRC xenograft models with anti-IL-6R antibody (tocilizumab) therapy. The IL-6R expression levels, histology of CRC growth/invasiveness, and tumor growth-related signaling pathway were estimated by H&E and immunohistochemical staining. SW480 tumor cells with higher IL-6R expression levels showed better responsiveness in tocilizumab therapy than in the treated HT-29 group. Likewise, therapeutic effects of tocilizumab on the proliferative ability with mitotic index and Ki-67 expressions, invasiveness with MMP-9 proteinase expressions, and ERK 1/2 and STAT3 signaling transduction in the SW480 treatment group were superior to the HT-29 treatment group. In light of our results, IL-6R is the key indicator for the efficacy of tocilizumab treatment in CRC xenografts. From the perspective of precision medicine, tumor response to anti-IL-6R antibody therapy could be predicted on the basis of IL-6R expression levels. In this manner, tocilizumab may serve as a targeted and promising anti-CRC therapy.
- Subjects
INTERLEUKIN-6 receptors; COLORECTAL cancer; IMMUNOSTAINING; XENOGRAFTS; TOCILIZUMAB
- Publication
Pharmaceuticals (14248247), 2024, Vol 17, Issue 1, p127
- ISSN
1424-8247
- Publication type
Article
- DOI
10.3390/ph17010127